|
1
|
Skeldon SC and Larry Goldenberg S: Bladder
cancer: A portal into men's health. Urol Oncol. 33:40–44. 2015.
View Article : Google Scholar
|
|
2
|
Malats N and Real FX: Epidemiology of
bladder cancer. Hematol Oncol Clin North Am. 29:177–189. vii2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pang KH and Catto JWF: Bladder cancer.
Surgery. 31:523–529. 2013.
|
|
4
|
Turo R, Cross W and Whelan P: Bladder
cancer. Medicine. 40:14–19. 2012. View Article : Google Scholar
|
|
5
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bellmunt J, Orsola A, Leow JJ, Wiegel T,
De Santis M and Horwich A: Bladder cancer: ESMO Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3):
iii40–iii48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sternberg CN, Bellmunt J, Sonpavde G,
Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ,
Milowsky MI, Theodorescu D, et al International Consultation on
Urologic Disease-European Association of Urology Consultation on
Bladder Cancer 2012: ICUD-EAU International Consultation on Bladder
Cancer 2012: Chemotherapy for urothelial carcinoma -neoadjuvant and
adjuvant settings. Eur Urol. 63:58–66. 2013. View Article : Google Scholar
|
|
8
|
Neoadjuvant chemotherapy in invasive
bladder cancer: Update of a systematic review and meta-analysis of
individual patient data advanced bladder cancer (ABC) meta-analysis
collaboration. Eur Urol. 48:202–205; discussion 205–206. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Julien S, Puig I, Caretti E, Bonaventure
J, Nelles L, van Roy F, Dargemont C, de Herreros AG, Bellacosa A
and Larue L: Activation of NF-kappaB by Akt upregulates Snail
expression and induces epithelium mesenchyme transition. Oncogene.
26:7445–7456. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar R, Deep G and Agarwal R: An overview
of ultraviolet B radiation-induced skin cancer chemoprevention by
silibinin. Curr Pharmacol Rep. 1:206–215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li F, Ma Z, Guan Z, Chen Y, Wu K, Guo P,
Wang X, He D and Zeng J: Autophagy induction by silibinin
positively contributes to its anti-metastatic capacity via
AMPK/mTOR pathway in renal cell carcinoma. Int J Mol Sci.
16:8415–8429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gu HR, Park SC, Choi SJ, Lee JC, Kim YC,
Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, et al: Combined treatment
with silibinin and either sorafenib or gefitinib enhances their
growth-inhibiting effects in hepatocellular carcinoma cells. Clin
Mol Hepatol. 21:49–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pirouzpanah MB, Sabzichi M, Pirouzpanah S,
Chavoshi H and Samadi N: Silibilin-induces apoptosis in breast
cancer cells by modulating p53, p21, Bak and Bcl-XL pathways. Asian
Pac J Cancer Prev. 16:2087–2092. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bosch-Barrera J and Menendez JA: Silibinin
and STAT3: A natural way of targeting transcription factors for
cancer therapy. Cancer Treat Rev. 41:540–546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prajapati V, Kale RK and Singh RP:
Silibinin combination with arsenic strongly inhibits survival and
invasiveness of human prostate carcinoma cells. Nutr Cancer.
67:647–658. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang K, Wang W, Jin X, Wang Z, Ji Z and
Meng G: Silibinin, a natural flavonoid, induces autophagy via
ROS-dependent mitochondrial dysfunction and loss of ATP involving
BNIP3 in human MCF7 breast cancer cells. Oncol Rep. 33:2711–2718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang
Z, Wang Z, Zhang D, Xue Y, Chen Y, et al: Chemopreventive and
chemotherapeutic effects of intravesical silibinin against bladder
cancer by acting on mitochondria. Mol Cancer Ther. 10:104–116.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayakawa M, Miyashita H, Sakamoto I,
Kitagawa M, Tanaka H, Yasuda H, Karin M and Kikugawa K: Evidence
that reactive oxygen species do not mediate NF-kappaB activation.
EMBO J. 22:3356–3366. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar
|
|
21
|
Herr HW, Dotan Z, Donat SM and Bajorin DF:
Defining optimal therapy for muscle invasive bladder cancer. J
Urol. 177:437–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li F, Zhang J, Arfuso F, Chinnathambi A,
Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: NF-κB in cancer
therapy. Arch Toxicol. 89:711–731. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gilmore TD and Wolenski FS: NF-κB: Where
did it come from and why? Immunol Rev. 246:14–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sui H, Zhu L, Deng W and Li Q:
Epithelial-mesenchymal transition and drug resistance: Role,
molecular mechanisms, and therapeutic strategies. Oncol Res Treat.
37:584–589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jung HJ, Park JW, Lee JS, Lee SR, Jang BC,
Suh SI, Suh MH and Baek WK: Silibinin inhibits expression of HIF-1α
through suppression of protein translation in prostate cancer
cells. Biochem Biophys Res Commun. 390:71–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim S, Choi JH, Lim HI, Lee SK, Kim WW,
Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ, et al: Silibinin prevents
TPA-induced MMP-9 expression and VEGF secretion by inactivation of
the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells.
Phytomedicine. 6:573–580. 2009. View Article : Google Scholar
|
|
27
|
Kim S, Kim SH, Hur SM, Lee SK, Kim WW, Kim
JS, Kim JH, Choe JH, Nam SJ, Lee JE, et al: Silibinin prevents
TPA-induced MMP-9 expression by down-regulation of COX-2 in human
breast cancer cells. J Ethnopharmacol. 126:252–257. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y,
Zhu G, Yang L, Wang X and He D: Silibinin reverses
epithelial-to-mesenchymal transition in metastatic prostate cancer
cells by targeting transcription factors. Oncol Rep. 23:1545–1552.
2010.PubMed/NCBI
|
|
29
|
Cufí S, Bonavia R, Vazquez-Martin A,
Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, Martin-Castillo B,
Barrajón-Catalán E, Visa J, Segura-Carretero A, et al: Silibinin
suppresses EMT-driven erlotinib resistance by reversing the high
miR-21/low miR-200c signature in vivo. Sci Rep. 3:24592013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun SC: The noncanonical NF-κB pathway.
Immunol Rev. 246:125–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Anreddy N, Gupta P, Kathawala RJ, Patel A,
Wurpel JN and Chen ZS: Tyrosine kinase inhibitors as reversal
agents for ABC transporter mediated drug resistance. Molecules.
19:13848–13877. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wellington K and Jarvis B: Silymarin: A
review of its clinical properties in the management of hepatic
disorders. BioDrugs. 15:465–489. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li L, Gao Y, Zhang L, Zeng J, He D and Sun
Y: Silibinin inhibits cell growth and induces apoptosis by caspase
activation, down-regulating survivin and blocking EGFR-ERK
activation in renal cell carcinoma. Cancer Lett. 272:61–69. 2008.
View Article : Google Scholar : PubMed/NCBI
|
